Editor's Note: This article was updated on Jul 18, 2019 at 10:53 PM GMT
In the latest sign of success for Bridge's strategy to translate first-in-class compounds discovered in Asia, the Korean biotech granted Boehringer exclusive global rights to its lung fibrosis candidate BBT-877.
The partnership is the
Read the full 332 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD